Switch theme
Sign up to access all valuation multiples
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
1970
3K+
LTM Revenue $963M
LTM EBITDA $217M
$4.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Novanta has a last 12-month revenue (LTM) of $963M and a last 12-month EBITDA of $217M.
In the most recent fiscal year, Novanta achieved revenue of $949M and an EBITDA of $180M.
Novanta expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Novanta valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $963M | XXX | $949M | XXX | XXX | XXX |
| Gross Profit | $441M | XXX | $422M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $217M | XXX | $180M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $174M | XXX | $124M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $79.3M | XXX | $64.1M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $303M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Novanta's stock price is $124.
Novanta has current market cap of $4.5B, and EV of $4.8B.
See Novanta trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.8B | $4.5B | XXX | XXX | XXX | XXX | $3.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Novanta has market cap of $4.5B and EV of $4.8B.
Novanta's trades at 5.0x EV/Revenue multiple, and 26.6x EV/EBITDA.
Equity research analysts estimate Novanta's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novanta has a P/E ratio of 56.1x.
See valuation multiples for Novanta and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.5B | XXX | $4.5B | XXX | XXX | XXX |
| EV (current) | $4.8B | XXX | $4.8B | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | 22.0x | XXX | 26.6x | XXX | XXX | XXX |
| EV/EBIT | 27.5x | XXX | 38.5x | XXX | XXX | XXX |
| EV/Gross Profit | 10.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 56.1x | XXX | 69.5x | XXX | XXX | XXX |
| EV/FCF | 34.8x | XXX | 33.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNovanta's last 12 month revenue growth is 5%
Novanta's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Novanta's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novanta's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Novanta and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novanta acquired XXX companies to date.
Last acquisition by Novanta was XXXXXXXX, XXXXX XXXXX XXXXXX . Novanta acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Novanta founded? | Novanta was founded in 1970. |
| Where is Novanta headquartered? | Novanta is headquartered in United States of America. |
| How many employees does Novanta have? | As of today, Novanta has 3K+ employees. |
| Who is the CEO of Novanta? | Novanta's CEO is Mr. Matthijs Glastra. |
| Is Novanta publicy listed? | Yes, Novanta is a public company listed on NAS. |
| What is the stock symbol of Novanta? | Novanta trades under NOVT ticker. |
| When did Novanta go public? | Novanta went public in 1999. |
| Who are competitors of Novanta? | Similar companies to Novanta include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Novanta? | Novanta's current market cap is $4.5B |
| What is the current revenue of Novanta? | Novanta's last 12 months revenue is $963M. |
| What is the current revenue growth of Novanta? | Novanta revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Novanta? | Current revenue multiple of Novanta is 5.0x. |
| Is Novanta profitable? | Yes, Novanta is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Novanta? | Novanta's last 12 months EBITDA is $217M. |
| What is Novanta's EBITDA margin? | Novanta's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Novanta? | Current EBITDA multiple of Novanta is 22.0x. |
| What is the current FCF of Novanta? | Novanta's last 12 months FCF is $138M. |
| What is Novanta's FCF margin? | Novanta's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Novanta? | Current FCF multiple of Novanta is 34.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
